Ablation vs Medication for AFib: Which Is Better?

Research-informed explainer — last updated 2026-04-11

For most patients with symptomatic atrial fibrillation, catheter ablation controls the irregular heartbeat more durably than antiarrhythmic medication — and in patients with comorbid heart failure, ablation has been shown to improve survival. Medication remains a reasonable first step for many patients, but the evidence increasingly supports offering ablation earlier, particularly for younger patients, those with paroxysmal (episodic) AFib, and anyone who has failed or cannot tolerate drug therapy.

This explainer draws on peer-reviewed research from three electrophysiologists listed in the Convene directory. Their published work includes the landmark CABANA trial, the worldwide catheter ablation survey, three international expert consensus statements, and a pivotal 2023 New England Journal of Medicine trial on next-generation ablation technology.

What is atrial fibrillation?

Atrial fibrillation (AFib) is the most common sustained cardiac arrhythmia, affecting more than 33 million people worldwide. In AFib, the upper chambers of the heart (the atria) fire chaotic electrical signals instead of beating in an organized rhythm. The result is an irregular, often rapid heartbeat that patients describe as fluttering, racing, or pounding in the chest, sometimes accompanied by shortness of breath, fatigue, or dizziness.

AFib is not just uncomfortable. It raises the risk of stroke by roughly five-fold and can weaken the heart over time. Treatment has two goals: controlling the heart rate or restoring a normal rhythm, and preventing stroke (usually with blood thinners, which are separate from the rhythm-control question addressed here).

What antiarrhythmic medications do

Antiarrhythmic drugs work by modifying the electrical signals inside heart cells. They fall into two broad strategies.

Rate control drugs (beta-blockers, calcium channel blockers, digoxin) slow the ventricular rate without trying to restore normal rhythm. The heart stays in AFib, but it beats more slowly and regularly enough that symptoms improve. Rate control is often the starting point for older patients or those with few symptoms.

Rhythm control drugs (flecainide, propafenone, sotalol, amiodarone, dofetilide) attempt to convert and maintain normal sinus rhythm. They are taken daily on an ongoing basis. They work, but imperfectly. Flecainide and propafenone are well-tolerated in patients without structural heart disease, but they cannot be used safely in patients with coronary artery disease or reduced heart function. Sotalol requires inpatient initiation due to a small risk of pro-arrhythmia. Amiodarone is highly effective but carries serious long-term risks: thyroid dysfunction, pulmonary toxicity, liver abnormalities, and sun sensitivity. Most electrophysiologists prefer to avoid amiodarone in younger patients when alternatives exist.

None of these drugs eliminate AFib permanently. Patients take them indefinitely, and efficacy tends to decline as the disease progresses.

What catheter ablation does

Catheter ablation targets the root cause of most AFib: abnormal electrical triggers that originate in or near the pulmonary veins, the four vessels that deliver oxygenated blood to the heart from the lungs. During the procedure, an electrophysiologist threads thin catheters through a vein in the groin into the heart and creates a ring of scar tissue around each pulmonary vein opening. This electrical isolation prevents the rogue signals from reaching the rest of the heart.

Most ablations today use radiofrequency energy (heat) or cryoablation (freezing) to create the scar. A newer approach, pulsed field ablation (PFA), delivers brief high-voltage electrical pulses that destroy heart tissue while largely sparing surrounding structures. A 2023 New England Journal of Medicine trial led in part by researchers at UCSF found pulsed field ablation noninferior to conventional thermal ablation for freedom from arrhythmia recurrence and adverse events at one year [7]. PFA is now available at major electrophysiology centers and may further reduce the already-low procedural risk of ablation.

The procedure typically takes two to four hours under sedation or general anesthesia and requires one to two days of recovery. Most patients return to normal activity within a week.

At a glance

What the CABANA trial found

The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial is the largest randomized controlled trial to directly compare these two strategies. It enrolled 2,204 patients with newly diagnosed or undertreated AFib at 126 centers in ten countries. Douglas Packer of Mayo Clinic was the first and corresponding author.

The primary composite endpoint — death, disabling stroke, serious bleeding, or cardiac arrest — was reduced by about 14% in the ablation group in the intent-to-treat analysis, but this difference did not reach statistical significance, likely because a large fraction of patients in the drug arm eventually crossed over to ablation (27.5%). In the per-protocol and on-treatment analyses, which account for actual treatment received, ablation significantly reduced the primary endpoint [1].

The clearest signal was for AFib recurrence. At five years, 47.3% of patients in the drug therapy group had experienced AFib recurrence compared to 27.5% in the ablation group — a 49% relative reduction, highly statistically significant (p<0.001) [1]. Patients who had ablation spent roughly half as many days in AFib compared to those on medication.

A companion paper in the same issue of JAMA analyzed quality of life using the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. Ablation patients had significantly better quality of life scores at 12 months [2]. The gap was clinically meaningful, not just statistically significant — ablation patients were doing better in their daily lives.

The heart failure subgroup: the strongest evidence

Patients who have both AFib and heart failure face the worst outcomes from either condition alone. The two diseases interact: AFib reduces the heart's pumping efficiency, and chronic AFib can cause or worsen heart failure through a mechanism called tachycardia-induced cardiomyopathy.

A 2021 analysis published in Circulation examined CABANA trial participants who had clinically diagnosed stable heart failure at enrollment [3]. In this subgroup, catheter ablation produced clinically important improvements in survival, freedom from AFib recurrence, and quality of life compared to drug therapy. The survival benefit — not just symptom improvement, but actual mortality reduction — was the most striking finding. For patients with AFib and heart failure, the evidence for ablation over medication is now compelling.

What the worldwide experience shows

The CABANA trial was a controlled experiment. The worldwide clinical experience is consistent with it. A survey of catheter ablation outcomes across major electrophysiology laboratories, involving tens of thousands of procedures, found that ablation was effective in approximately 80% of patients after an average of 1.3 procedures per patient. Approximately 70% of those patients did not need to resume antiarrhythmic drugs during intermediate follow-up [4]. That survey, authored in part by Hugh Calkins of Johns Hopkins, helped establish catheter ablation as the most effective available rhythm-control strategy for AFib.

How the guidelines evolved

Medical guidelines reflect the accumulated weight of evidence. The trajectory on catheter ablation has moved consistently in one direction.

The 2012 expert consensus statement from the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), and the European Cardiac Arrhythmia Society (ECAS) — co-authored by Hugh Calkins — stated that catheter ablation was a reasonable approach for symptomatic AFib patients who had failed or were intolerant to antiarrhythmic drugs, and noted that ablation was increasingly being considered as first-line therapy for selected younger patients with paroxysmal AFib [5]. Ablation was not yet the default, but it was no longer a last resort.

The 2017 update to those consensus guidelines — co-authored by Edward Gerstenfeld of UCSF among others — elevated the evidence base further [6]. Ablation received a Class I recommendation (highest evidence level) for symptomatic paroxysmal AFib after failure of antiarrhythmic drug therapy. For selected patients as first-line therapy, ablation received a Class IIa recommendation. The guidelines continued to move in 2020 and 2023, with some societies now endorsing ablation as reasonable first-line therapy in broader populations.

Who benefits most from ablation

The evidence most strongly supports choosing ablation over medication in these situations:

Symptomatic patients who have already tried medication. If you have taken a rhythm-control drug and AFib keeps recurring, or you have had to stop the drug because of side effects, ablation is the next logical step and carries strong guideline support.

Younger patients with paroxysmal AFib. Paroxysmal AFib (episodic rather than continuous) is more reliably treated with ablation. Younger patients have more to gain from long-term rhythm control and more to lose from decades of antiarrhythmic drug use.

Patients with AFib and heart failure. The CABANA heart failure subgroup analysis provides the strongest evidence base here. If you have reduced ejection fraction or clinically diagnosed heart failure alongside AFib, ablation deserves serious consideration regardless of prior drug therapy.

Patients who want to reduce or eliminate medication. After successful ablation, most patients can discontinue antiarrhythmic drugs. About 70% in the worldwide survey needed no further antiarrhythmic therapy.

When medication is still appropriate

Ablation is not for everyone. Medication — including rate control without any attempt at rhythm restoration — remains a reasonable and guideline-supported strategy for:

Older or frail patients in whom procedural risk is elevated or whose symptoms are manageable with rate control alone. For patients who are minimally symptomatic or who primarily need rate control to prevent tachycardia, adding a daily beta-blocker or calcium channel blocker may be all that is needed.

Patients who prefer to avoid a procedure. Ablation is generally safe in experienced hands, but it is still an invasive procedure with a small risk of serious complications. Some patients, after hearing the options, reasonably prefer to try medication first.

Patients with significant comorbidities that increase procedural risk, such as severe obesity, advanced lung disease, or bleeding disorders that make catheter manipulation more hazardous.

Persistent or long-standing persistent AFib in older patients who are less likely to maintain sinus rhythm even after ablation. Success rates for ablation decline as AFib becomes more continuous and the atria remodel over time.

Understanding procedural risk

The most common serious complication of catheter ablation is cardiac tamponade — bleeding into the sac around the heart — which occurs in approximately 0.5 to 1% of procedures at experienced centers and is typically treated with drainage rather than surgery. Pulmonary vein stenosis (narrowing of the vein openings) was more common with early techniques and is now rare with modern energy delivery. Stroke risk during the procedure is small and is mitigated with anticoagulation before and during the procedure.

Overall, catheter ablation at a high-volume center has a serious complication rate well under 2% and a procedure-related mortality rate of approximately 0.1%. These numbers matter for putting the benefits in context: for the right patient, the risk-benefit calculation generally favors ablation.

Questions to ask your electrophysiologist

• Is my AFib paroxysmal, persistent, or long-standing persistent, and how does that affect my options?
• Have I been on a rhythm-control medication that has not worked, and does that make ablation more appropriate now?
• Do I have any heart failure or reduced ejection fraction that would strengthen the case for ablation?
• What is your center's volume of AFib ablations per year, and what are your complication rates?
• If ablation is recommended, would conventional thermal ablation or pulsed field ablation be used at your center?
• What are the chances I will need a repeat procedure, and how would my care be managed if AFib recurs?
• Regardless of rhythm management, what is my recommended anticoagulation plan for stroke prevention?

The bottom line

The evidence from the CABANA trial and more than two decades of worldwide clinical data point in the same direction: catheter ablation is the most effective rhythm-control strategy for atrial fibrillation, producing better freedom from AFib recurrence, better quality of life, and — in patients with heart failure — better survival compared to antiarrhythmic medication. Medication still plays an important role, particularly for older patients, those with minimal symptoms, or those who prefer to avoid a procedure. But the old model of medication first, ablation only as a last resort, has given way to a more nuanced view in which ablation is offered earlier to symptomatic patients who are good procedural candidates. If you have AFib and your symptoms are not well controlled on medication — or if you simply want to explore your options — a consultation with a board-certified cardiac electrophysiologist is the right next step.